Document Detail

Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
MedLine Citation:
PMID:  11887179     Owner:  NLM     Status:  MEDLINE    
Recently, a new slow-release (SR) formulation of lanreotide (LAN) comprising 60 mg of the drug incorporated in microspheres of biodegradable polymers (SR-LAN 60) has become available. The aim of our study was to assess the effectiveness of SR-LAN 60, administered every 21 to 28 days, as well as its tolerability in the long-term treatment of acromegalic patients treated with SR-LAN 30. Twenty patients with acromegaly (10 males and 10 females) were enrolled in this open study. Thirteen patients had undergone surgery, but with incomplete resection of the pituitary tumor. All patients, treated with intramuscular (IM) SR-LAN 30 injections every 10 days for 12 to 24 months, started SR-LAN 60 (Ipsen-Beaufour, Milan, Italy) administration 10 days after the last injection of SR-LAN 30. Growth hormone (GH) levels were determined on the day of the first injection of SR-LAN 60, and 10, 20, and 30 days after. According to the GH levels reached on day 30, patients received SR-LAN 60 every 28 days if GH levels were below 2.5 microg/L (group A) and every 21 days if GH levels were above 2.5 microg/L (group B). In group A, after the 8th month, SR-LAN 60 treatment resulted in well-controlled GH levels in 9 of 10 patients in comparison to SR-LAN 30 treatment every 10 days (6 of 10 patients). Normal age-adjusted insulin-like growth factor-I (IGF-I) levels were achieved in 4 of 10 patients, as in treatment with SR-LAN 30. In group B, SR-LAN 60 treatment resulted in well-controlled GH levels in 4 of 10 patients, as in treatment with SR-LAN 30 every 10 days. Normal age-adjusted IGF-I levels were achieved in 3 of 10 patients after SR-LAN 60 in comparison to SR-LAN 30 treatment every 10 days (1 of 10 patients). During SR-LAN 60 therapy, an improvement was also observed in signs and symptoms of active acromegaly and no relevant side effects were detected. In conclusion, this study shows that SR-LAN 60 treatment is able to induce a good control of circulating GH and IGF-I levels in most acromegalic patients. The first injections of SR-LAN 60 are very helpful in predicting the optimal long-term injection frequency. Patients on SR-LAN 30 can be safely and effectively shifted to SR-LAN 60.
Maria Rosaria Ambrosio; Paola Franceschetti; Marta Bondanelli; Mauro Doga; Pietro Maffei; Roberto Baldelli; Guido Tamburrano; Nicola Sicolo; Andrea Giustina; Ettore C degli Uberti
Related Documents :
10833209 - A preliminary study of growth hormone therapy for crohn's disease.
16010459 - Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases.
8430559 - Normal ovaries in neonates and infants: a sonographic study of 77 patients 1 day to 24 ...
15671089 - Short-term effects of growth hormone (gh) treatment or deprivation on cardiovascular ri...
19147599 - Long-term treatment of acromegalic patients resistant to somatostatin analogues with th...
15177699 - The effect of growth hormone substitution on cognitive performance in adult patients wi...
21531529 - Impact of renal insufficiency on clinical outcomes in patients with critical limb ische...
12004019 - Total hip replacement with a cementless acetabular component and a cemented femoral com...
23999209 - The accuracy of component alignment in custom cutting blocks compared with conventional...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  51     ISSN:  0026-0495     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  2002 Mar 
Date Detail:
Created Date:  2002-03-11     Completed Date:  2002-03-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  United States    
Other Details:
Languages:  eng     Pagination:  387-93     Citation Subset:  IM    
Copyright Information:
Copyright 2002 by W.B. Saunders Company
Department of Biomedical Sciences and Advanced Therapies, Section of Endocrinology, University of Ferrara, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acromegaly / blood,  drug therapy*,  physiopathology
Delayed-Action Preparations
Dose-Response Relationship, Drug
Drug Administration Schedule
Human Growth Hormone / blood
Injections, Intramuscular
Insulin-Like Growth Factor I / metabolism
Middle Aged
Peptides, Cyclic / administration & dosage*,  adverse effects,  therapeutic use
Somatostatin / administration & dosage*,  adverse effects,  analogs & derivatives,  therapeutic use
Treatment Outcome
Reg. No./Substance:
0/Delayed-Action Preparations; 0/Peptides, Cyclic; 118992-92-0/lanreotide; 12629-01-5/Human Growth Hormone; 51110-01-1/Somatostatin; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phosphatidylinositol 3-kinase may mediate isoproterenol-induced vascular relaxation in part through ...
Next Document:  A novel mutation in the intron 1 splice donor site of the cholesterol ester transfer protein (CETP) ...